Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01046734
Other study ID # 09061
Secondary ID
Status Completed
Phase N/A
First received January 11, 2010
Last updated September 26, 2012
Start date September 2009
Est. completion date March 2011

Study information

Verified date September 2012
Source University of Nottingham
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Department of HealthUnited Kingdom: National Health ServiceUnited Kingdom: Research Ethics Committee
Study type Observational

Clinical Trial Summary

An influenza pandemic has recently been declared, involving the novel A(H1N1) 'swine flu' virus. This has spread to almost 100 countries worldwide in less than two months, causing widespread disease so far in Mexico, USA and Canada. It is highly likely that over the next 12 months, many countries including the UK will be affected by widespread illness. In the UK this wave of intense flu activity is most likely to occur in late autumn 2009.

Very little is known about the new H1N1 pandemic virus. For example we do not know how long the virus is excreted by infected humans and how much virus is spread to surfaces and carried in the air. This is very important to know as soon as possible because it affects the advice that will be given to healthcare workers about controlling the spread of infection to themselves and other patients. Similarly we need this information so we can give good quality advice to families who will have to look after each other in their own homes.

The best way to obtain this information is to ask patients who get pandemic flu soon (in August, September and October) to help us by agreeing to give a daily nose swab sample for just over one week so we can see how much virus is in the nose day by day and how quickly this disappears. At the same time we will take samples from hard surfaces in a patient's room or home and sample the air using a special filter device. We can then work out how much virus is being excreted, how long the 'danger period' is, whether surfaces are more or less important than the air that we breathe (in terms of catching the virus) and if we can advise on a 'safe distance' from the patient, beyond which there is relatively little chance of catching the illness.


Recruitment information / eligibility

Status Completed
Enrollment 105
Est. completion date March 2011
Est. primary completion date March 2011
Accepts healthy volunteers No
Gender Both
Age group 1 Month and older
Eligibility Inclusion Criteria:

- Subject fulfils case definition

- Informed consent obtained (from Parent/Guardian where appropriate)

- Age >1 month

- Near-patient test positive for influenza A or other substantive test positive for influenza A (including 'swine flu')

- Willing to participate and agrees to allow both nasal and environmental samples to be taken

Exclusion Criteria:

- Illness for >48h (community cases)

- Illness for >96h (hospital cases)

- Existing case of ILI in the household

- A negative for swine flu (as part of NHS care)

- Has taken part in influenza research involving an investigational medicinal product within the last 3 months

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
United Kingdom Leicester University Hospitals NHS Trust Leicester
United Kingdom Nottingham University Hospitals NHS Trust Nottingham
United Kingdom Sheffield Teaching Hospitals NHS Trust Sheffield

Sponsors (1)

Lead Sponsor Collaborator
University of Nottingham

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Virus shedding and deposition as measured by virus culture and quantitative polymerase chain reaction (PCR). 6 months No